North Carolina

North Carolina’s 2025-2026 bills are notable chiefly because they frame psychedelics inside mental-health research and task-force language, not legal adult access. S568 is a task-force bill. S1018 is wider than psychedelics, but its text specifically contemplates grant-supported research involving psilocybin concentrated on anxiety disorder, depressive disorder, or both. That is a meaningful policy signal, but it is not an authorisation for clinical use outside research.###

For access researchers, that distinction matters. North Carolina is exploring evidence development and governance, not near-term public access. If either bill moved, the immediate output would be studies, recommendations, and grants rather than patient-facing psilocybin services.###

North Carolina has real but still uneven research visibility. Duke Medicine has publicly highlighted scholars studying how psychedelic compounds might become alternative treatments for difficult conditions. ClinicalTrials.gov also lists a North Carolina location in Waynesville, at The Pearl Institute, for an MDMA-assisted therapy study for stress disorders in healthcare providers.###

The in-state lawful treatment infrastructure is clearer for ketamine/esketamine than for classical psychedelics. UNC’s Interventional Psychiatry Clinic openly offers intranasal esketamine, which makes North Carolina relevant for patient-access research on what “ordinary lawful” access looks like in a non-psilocybin-programme state.###

Because no psilocybin bill has been enacted, there is no current statewide implementation machinery for licensing, facilitator training, service centres, or public data reporting. The only concrete implementation path visible in the current NC legislation is advisory or research-oriented: a task force in S568 and grant/research structures in S1018.###

That means operational uncertainty is total for any future classical psychedelic system. No lead regulator, provider standard, procurement path, or reimbursement scheme for psilocybin services has been verified. North Carolina should therefore be read as a research-policy state, not an implementation state.###

The most visible ecosystem anchors in the reviewed source set are Duke, UNC, and the Pearl Institute. Duke contributes academic and translational interest; UNC anchors ordinary lawful esketamine care in a public academic psychiatry setting; and the Pearl Institute appears on the trial registry as a North Carolina MDMA study location.###

North Carolina does not yet show the same obvious public-facing psychedelic ecosystem density as New York. For conference and partner mapping, the state currently looks strongest in academic psychiatry, mental-health policy, and trial-site potential rather than in a mature advocacy-plus-services-plus-regulation stack.###

North Carolina’s next 12 to 24 months are likely to centre on whether lawmakers want to formalise a study-and-task-force route or let the issue remain at the level of academic and sponsor-led research. The HEAL Act gives the state a way to support evidence generation without taking the political step of authorising medical psilocybin access.###

Actual patient access is therefore unlikely to change quickly unless a much stronger clinical-access bill appears. The most immediate watch items are S1018’s appropriations path, any reactivation of S568, and whether North Carolina’s academic institutions increase their role in sponsor-led trials. Reimbursement change is most plausible first for ordinary esketamine/ketamine delivery, not for psilocybin.###